Bausch & Lomb, Santen Strike Licensing Agreement for IOL Development
Under the terms of the agreement, Bausch & Lomb has obtained the rights to Santen’s hydrophobic acrylic polymers, from which it may commercialize new IOLs for sale worldwide. Santen reserves the right for the use of these materials in the Japanese market. Financial terms will not be disclosed.
“Bausch & Lomb is enthusiastic about the potential that these polymers hold for developing next-generation IOLs, to benefit patients and surgeons alike,” said
“Developing these novel materials extends our access to the global IOL marketplace, complementing our existing Crystalens(R), Akreos(TM) and SofPort(R) IOL products,” noted
Bausch & Lomb is one of the world’s leading developers and manufacturers of IOLs, which are used to replace the eye’s natural crystalline lens during cataract surgery. Its Crystalens product is the only FDA-approved accommodating IOL, flexing like the eye’s natural lens to allow patients to see better at all distances.
About Bausch & Lomb
Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life for people around the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Bausch & Lomb is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in
Akreos, SofPort, and Crystalens are trademarks of Bausch & Lomb Incorporated.
SOURCE Bausch & Lomb
